Onderzoeker
Sylvie Rottey
- Disciplines:Kankertherapie, Oncologie niet elders geclassificeerd, Kankerbiologie
Affiliaties
- Vakgroep Fundamentele en Toegepaste Medische Wetenschappen (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Farmacologie (Departement)
Lid
Vanaf1 okt 2008 → 30 sep 2018
Projecten
1 - 2 of 2
- Universeel, kosten-effectief open-source technologieplatform voor lichaamsvloeistof-biopsie met hoge gevoeligheid, gebaseerd op het profileren van het methyloom van circulerend DNA.Vanaf1 jan 2024 → HedenFinanciering: BOF - projecten
- Predictie van immuuntherapie response en toxiciteit in melanoom, nier- en longkanker door een transcriptoom gebaseerde immuun profilering.Vanaf1 nov 2021 → HedenFinanciering: FWO mandaten
Publicaties
21 - 30 van 103
- Isatuximab plus atezolizumab in patients with advanced solid tumors : results from a phase I/II, open-label, multicenter study(2022)
Auteurs: M. Simonelli, E. Garralda, F. Eskens, M. Gil-Martin, C-J Yen, R. Obermannova, Y. Chao, S. Lonardi, B. Melichar, V Moreno, et al.
- Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis : a randomized, placebo-controlled phase 1 trial(2021)
Auteurs: Randolph P. Matthews, Munjal Patel, Stephanie E. Barrett, Liesbeth Haspeslagh, Tom Reynders, Saijuan Zhang, Sylvie Rottey, Adrian Goodey, Ryan C. Vargo, Jay A. Grobler, et al.
Pagina's: 1712 - 1717 - An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma(2021)
Auteurs: Tijl Vermassen, David Creytens, Stijn De Keukeleire, Tim Delahaye, Philippe Deron, Fréderic Duprez, Samson Fung, Patrick Pauwels, Liesbeth Ferdinande, Sylvie Rottey
Pagina's: 2300 - 2313 - Immuno-oncological biomarkers for squamous cell cancer of the head and neck : current state of the art and future perspectives(2021)
Auteurs: Stijn De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
- Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer(2021)
Auteurs: Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, et al.
- Anthracyclines strike back : rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer(2021)
Auteurs: Francesco Schettini, Mario Giuliano, Matteo Lambertini, Rupert Bartsch, David James Pinato, Concetta Elisa Onesti, Nadia Harbeck, Diana Lueftner, Sylvie Rottey, Peter A. van Dam, et al.
- Retrospective analysis of mpMRI to predict complete pathologic response after neo-adjuvant chemotherapy for muscle invasive bladder cancer(2021)Volume: 39
Auteurs: Daan De Maeseneer, Pieter De Visschere, Mats Van den broecke, Geert Villeirs, Karel Decaestecker, Sylvie Rottey
Aantal pagina's: 1 - Expected medium- and long-term impact of the COVID-19 outbreak in oncology(2021)
Auteurs: Concetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, Nadia Harbeck, Rupert Bartsch, Hans Wildiers, Vivianne Tjan-Heijnen, Miguel Martin, Sylvie Rottey, Daniele Generali, et al.
Pagina's: 162 - 172 - Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures(2021)
Auteurs: Annabel Meireson, Simon Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, et al.
- A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck : the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial(2021)
Auteurs: Rachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, Amaury Daste, Caroline Even, Philip Debruyne, Stéphanie Henry, Sylvie Zanetta, Anemie Rutten, Lisa Licitra, et al.
Pagina's: 17 - 26